ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2009
Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Lactate drives cellular DNA repair capacity: Role of lactate and related short-chain fatty acids in cervical cancer chemoresistance and viral infection.Frontiers in cell and developmental biology · 2022Review
- Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency.PLoS pathogens · 2018Article
- Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.Molecular cancer therapeutics · 2017Article
- Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.The Journal of clinical investigation · 2016Review
- Review
- Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.Journal of virology · 2014Article
- Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.Molecular cancer therapeutics · 2014Article
- Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.Current opinion in oncology · 2011Review
- Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.Journal of virology · 2011Article
- Article
- Update on HHV-8-Associated Malignancies.Current infectious disease reports · 2010Article
- Molecular and therapeutic potential and toxicity of valproic acid.Journal of biomedicine & biotechnology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 1 country.
Funding
Abstract
The AIDS Malignancy Consortium undertook a pilot trial of valproic acid among patients with AIDS-associated Kaposi sarcoma (KS). Treatment was associated with low toxicity, but the KS clinical response and KS herpesvirus lytic induction rates were not sufficiently high to meet predefined criteria for efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.